In a statement, Novo Nordisk, maker of the GLP-1 drug semaglutide, noted, For Wegovy specifically, animal studies suggest there may be risks to the fetus, and weight loss during pregnancy offers no benefit and may cause harm
its an opportunity to completely reset your relationship with food and nutrition
However, clinical observations noted that many patients on semaglutide experienced significant weight loss as a secondary benefit
[36, 37] Unlike conventional hypodermic needles, microneedle systems create transient microchannels that bypass the stratum corneum, enabling efficient transdermal transport of a wide range of molecules, including peptides, proteins, and small drugs, without reaching nerve-rich deeper layers and thus minimizing pain and risk of infection [38, 39]